

Insulin Resistance in Chronic Hepatitis B virus infection

Thesis

Submitted for Partial Fulfillment of Master Degree
in **Internal Medicine**

By

Amira Isaac Samaan

M.B., B.Ch.

Ain Shams University

Under Supervision of

Prof. Yehia Mohamed El Shazly

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Prof. Raef Malak Botrous

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Reham Ezzat Al Swaff

Lecturer of Internal Medicine

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2011

مقاومة الإنسولين فى الإلتهاب الكبدى الفيروسى المزمن (ب)

رسالة

توطئة للحصول على درجة الماجستير
فى أمراض الباطنة

مقدمة من

الطبيبة / أميرة إسحاق سمعان
بكالوريوس الطب والجراحة

تحت إشراف

الأستاذ الدكتور / يحيى محمد الشاذلى

استاذ الباطنة العامة
كلية الطب- جامعة عين شمس

الأستاذ الدكتور / رائف ملاك بطرس

أستاذ الباطنة العامة والغدد
كلية الطب- جامعة عين شمس

الدكتورة / ريهام عزت الصواف

مدرس الباطنة العامة
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١١

Summary

This study was carried out in the department of internal medicine, Ain Shams University hospital.

50 subjects were included and were divided into two groups: Group (A) 35 patients with chronic hepatitis B virus infection and Group (B) 15 healthy volunteers.

The aim of this study was to determine whether insulin resistance occurs in patients with chronic hepatitis B virus infection.

HOMA insulin resistance index was found to be within normal range among chronic HBV infected patients, and all variables (except serum ALT level) were comparable between patients and control group.

Insignificant differences were found between average weight and overweight chronic HBV infected patients as regards all parameters exploring insulin resistance.

List of Contents

Title	Page No.
List of Figures	<i>i</i>
List of Tables	<i>ii</i>
List of Abbreviations	<i>iv</i>
Introduction	1
Aim of the work	2
Review of Literature	3
Chapter I: Hepatitis B Virus infection	3
❑ Structure of HBV	4
❑ Life cycle of HBV	7
❑ Transmission of HBV	9
❑ HBV induced inflammatory reaction	12
❑ Clinical picture of HBV infection	13
- Acute hepatitis B	13
- Chronic hepatitis B	14
- Stages of chronic HBV infection.....	14
❑ Consequences of chronic HBV infection	22
❑ Extrahepatic manifestations of HBV infection.....	24
❑ Clinical diagnosis	29
- Acute hepatitis B	29
- Chronic hepatitis B	30
❖ Biochemical diagnosis.....	30
❖ Virological diagnosis.....	32
❖ Serological diagnosis.....	33
❖ Histological diagnosis	36

❑ Management of chronic HBV infection	39
- HBV therapies	39
❑ Treatment recommendation for chronic HBV infection.....	46
- HBeAg positive patients.....	46
- HBeAg negative patients	48
- Patients with cirrhosis.....	49
❑ Other treatments of HBV	50
Chapter II: insulin resistance and chronic liver disease	54
❑ Insulin resistance.....	54
❑ Insulin resistance and chronic liver disease.....	57
❑ Insulin resistance and NAFLD	59
❑ Insulin resistance and cirrhosis	60
❑ Insulin resistance and viral hepatitis.....	62
- Insulin resistance and HCV	63
❑ Therapeutic strategies for insulin resistance.....	66
Chapter III: insulin resistance and HBV	68
Subjects and methods	72
Results	75
Discussion.....	84
Summary.....	89
Conclusion and Recommendations	90
References	91
Arabic Summary	

List of Figures

Fig. No.	Title	Page No.
Figure (1):	The partially double-strand circular genome of hepatitis B virus: S for the surface gene, C for the core gene, P for the core gene, P for the polymerase gene and X for X gene	5
Figure (2):	Hepatitis B virus establishes covalently closed circular DNA (cccDNA) as a durable miniature chromosome in the host nucleus and relies on a retroviral strategy of reverse transcription from RNA to negative-strand DNA	8

List of Tables

Table No.	Title	Page
Table (1):	Phases of chronic HBV infection according to different diagnostic tools	21
Table (2):	The serological markers in different phases of HBV infection	36
Table (3):	Ishak Modified HAI (scoring and grading)	38
Table (4):	Comparison between group A (hepatitis B patients) and group B (control) as regard the mean age and BMI.....	76
Table (5):	Comparison between group A (hepatitis B patients) and group B (control) as regard gender	77
Table (6):	Comparison between group A (hepatitis B patients) and group B (control) as regard different biochemical variables	78
Table (7):	Comparison between average weight and overweight cases (group A), as regard the mean fasting glucose, 2 hours PP, fasting Insulin and HOMA insulin resistance index	79
Table (8):	Comparison between average weight and overweight controls (group B), as regards the mean fasting glucose, 2 hours PP, fasting Insulin and HOMA insulin resistance index.....	80
Table (9):	Correlation between ALT level, BMI and studied parameters among average weight chronic HBV infected patients	81

Table (10): Correlation between ALT level, BMI and studied parameters among overweight chronic HBV infected patients	82
Table (11): Correlation between ALT level, BMI and studied parameters among average weight control subjects	83
Table (12): Correlation between ALT, BMI and studied parameters among overweight control subjects.....	84

List of Abbreviations

α1 ATD	: α 1 antitrypsin deficiency
αFP	: Alpha fetoprotein
Akt	: Alpha serine/threonine protein kinase
ALT	: Alanine transaminase
AMP	: Adenosine mono phosphate
AST	: Aspartate transaminase
BMI	: Body mass index
BUN	: Blood urea nitrogen
cccDNA	: Covalently closed circular DNA
CD	: Cluster of differentiation
CHB	: Chronic hepatitis B
CHC	: Chronic hepatitis C
CK	: Creatinine kinase
CLD	: Chronic liver disease
DCs	: Dendritic cells
DM	: Diabetes Mellitus
DPP-4	: Dipeptidyl peptidase-4
ELISA	: Enzyme linked immune sorbant assay
FFA	: Free fatty acids
FSIVGTT	: Frequently sampled IV glucose tolerance test
HAI	: Histologic activity index
HAV	: Hepatitis A virus
HBc Ab	: Hepatitis B core antibody
HBe Ab	: Hepatitis B envelope antibody
HBe Ag	: Hepatitis B envelope antigen
HBV	: Hepatitis B virus
HBVsAb	: Hepatitis B surface antibody

HBVsAg	: Hepatitis B surface antigen
HBX	: Hepatitis B virus X protein
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HCVA_b	: Anti hepatitis C virus antibody
HDV	: Hepatitis D virus
HIV	: Human immunodeficiency virus
HOMA-IR	: Homeostasis Model assessment
IFNs	: Interferons
IL	: Interleukin
INR	: International normalization ratio
IR	: Insulin resistance
IRS	: Insulin receptor substrates
MHC	: Major histocompatibility complex
mRNA	: Messenger RNA
MS	: Metabolic syndrome
NAFLD	: Non alcoholic fatty liver disease
NAs	: Nucleoside or nucleotide analogs
NASH	: Non Alcoholic Steato Hepatitis
NFKB	: Nuclear Factor-KappaB
NK	: Natural killer cells
OGTT	: Oral glucose tolerance test
ORF	: Open reading frame
OS	: Oxidative stress
PBC	: Primary biliary cirrhosis
PCR	: Polymerase Chain Reaction
PEG	: Polyethylene glycol
PI3K	: Phosphatidylinositol- 3-kinase
PPAR_γ	: Peroxisome proliferator activated receptor gamma
PSC	: Primary sclerosing cholangitis

PT	: Prothrombin time
SOCS3	: Suppressor of cytokine signaling-3 gene
T2DM	: Type 2 diabetes mellitus
TGF-β1	: Transforming growth factor-beta 1
Th17	: T helper 17
TNF	: Tumor necrosis factor
ULN	: Upper Limit of Normal
USFDA	: United States Food and Drug Administration
WBISI	: Whole-body insulin sensitivity index

Acknowledgement

*Thanks first and last to **God** as we owe to him for his great care, support and guidance in every step in our life.*

*I would like to express my sincere gratitude to **Prof. Dr. Yehia Mohamed El Shazly**, Professor of internal Medicine, Faculty of Medicine, Ain Shams University who has so kindly supervised my thesis, I am deeply grateful to him for his professional advice, his guidance and support.*

*I wish also to express my gratitude to **Prof. Dr. Raef Malak Botrous**, Professor of internal Medicine, Faculty of Medicine, Ain Shams University under his supervision and kind advice, I had the honor to complete this work.*

*I am also greatly indebted to **Dr. Reham Ezzat Al Swaff**, Lecturer of internal Medicine, Faculty of Medicine, Ain Shams University for her enthusiasm and help.*

Amira Isaac

Introduction

Incidence of diabetes mellitus in adults with chronic hepatitis B virus infection is four times higher than that in the general population (22.5%) (*Custro et al., 2001*).

Prospective studies have shown that insulin resistance precedes the onset of diabetes by 10-20 years; also the presence of diabetes may be associated with increased rate of progression of fibrosis in patients with chronic hepatitis C and chronic hepatitis B virus infection (*Hui et al., 2003*).

Patients with chronic hepatitis have impaired glucose metabolism with hyperinsulinemia and insulin resistance, this hyperinsulinemia has been shown to be due to decreased insulin catabolism rather than increased pancreatic insulin secretion (*Greco et al., 2002*).

Persico et al. (2009) reported higher prevalence of metabolic syndrome and diabetes mellitus in patients with hepatitis C virus than in patients with hepatitis B virus related chronic liver disease.

Recent years have seen numerous studies devoted to the relationship between chronic hepatitis C virus infection and insulin resistance. However no sufficient data are available for the relationship between chronic hepatitis B virus infection and insulin resistance.

Aim of the work

The aim of this study is to determine whether insulin resistance occurs in patients with chronic hepatitis B virus infection.

Hepatitis B Virus Infection

Hepatitis B virus (HBV) infection is highly prevalent worldwide and is a major cause of morbidity and death. Two billion people globally have been infected with HBV, 350 to 400 million are chronic carriers, and tens of millions of new cases occur annually (*Carey, 2009*).

Some individuals can develop acute HBV infection and achieve complete immune clearance of virus, yielding a life-long immunity, while others can develop chronic HBV infection depending on the host immune response. Chronic HBV infection is associated with a wide range of clinical manifestations, from an asymptomatic carrier state with a normal liver histology to severe and chronic liver diseases, including cirrhosis and hepatocellular carcinoma (*McMahon, 2005*).

Geographic Distribution of Chronic HBV Infection:

The global prevalence of HBV varies widely. Regions are divided into areas of low, intermediate, and high prevalence, defined as follows:

High prevalence implies that at least 8% of the population is currently infected. About 45% of the world's population lives in regions of high prevalence. Among this group, early childhood infections are common, with the virus usually transmitted from mother to infant during the perinatal period. These regions include South East Asia, China, the Amazon area, and sub-Saharan Africa (*Heathcote et al., 2008*).